Literature DB >> 15848735

The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms.

Ming Zhou1, Andres Roma, Cristina Magi-Galluzzi.   

Abstract

Histologic subtyping of RCC has been shown to be of prognostic value; therefore, it is important to classify malignant epithelial tumors of the kidney correctly and also to differentiate them from benign ones. Overlapping morphologic features of renal tumors sometimes make histologic subtyping difficult. The accurate diagnosis and classification of RCC are based on cytoarchitectural features and require correlation with immunophenotype and cytogenetic characteristics. RCC Ma and CD10, two markers with relative renal specificity, have been used to confirm a diagnosis of suspected RCC and can facilitate the accurate diagnosis of metastatic RCC, in particular, in FNA. Although CCRCC and PRCC share most immunomarkers, CK7 and AMACR expression can be helpful in the differential diagnosis of challenging histologic variants of the two. In addition, E-cadherin aids in the distinction between types 1 and 2 PRCC. Useful markers in the differential diagnosis between ChRCC and CCRCCare CK7, RCC Ma, CD10, VIM, CD117, parvalbumin, and E-cadherin. We propose CK7/CK20/CD15 as a useful primary immunopanel to differentiate ChRCC from ONC reliably.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15848735     DOI: 10.1016/j.cll.2005.01.004

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN: 0272-2712            Impact factor:   1.935


  32 in total

1.  Renal tumors: diagnostic and prognostic biomarkers.

Authors:  Puay Hoon Tan; Liang Cheng; Nathalie Rioux-Leclercq; Maria J Merino; George Netto; Victor E Reuter; Steven S Shen; David J Grignon; Rodolfo Montironi; Lars Egevad; John R Srigley; Brett Delahunt; Holger Moch
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

2.  MR Imaging of papillary renal neoplasms: potential application for characterization of small renal masses.

Authors:  Catherine Roy; Benoit Sauer; Véronique Lindner; Hervé Lang; Christian Saussine; Didier Jacqmin
Journal:  Eur Radiol       Date:  2006-06-07       Impact factor: 5.315

3.  Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients.

Authors:  Chiara Grisanzio; Apryle Seeley; Michelle Chang; Michael Collins; Arianna Di Napoli; Su-Chun Cheng; Andrew Percy; Rameen Beroukhim; Sabina Signoretti
Journal:  J Pathol       Date:  2011-06-27       Impact factor: 7.996

4.  Giant renal oncocytoma with classic stellate scar.

Authors:  Rachael D Sussman; Keith J Kowalczyk
Journal:  BMJ Case Rep       Date:  2017-01-27

Review 5.  Oxygenomics in environmental stress.

Authors:  H Sone; H Akanuma; T Fukuda
Journal:  Redox Rep       Date:  2010       Impact factor: 4.412

6.  Cadherin 17 is a sensitive and specific marker for metanephric adenoma.

Authors:  Evgeny Yakirevich; Cristina Magi-Galluzzi; Zakaria Grada; Shaolei Lu; Murray B Resnick; Shamlal Mangray
Journal:  Am J Surg Pathol       Date:  2015-04       Impact factor: 6.394

7.  Tubulocystic carcinoma of the kidney: a histologic, immunohistochemical, and ultrastructural study.

Authors:  Borislav A Alexiev; Cinthia B Drachenberg
Journal:  Virchows Arch       Date:  2013-03-24       Impact factor: 4.064

8.  Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent.

Authors:  Adolfo Varona; Lorena Blanco; Itxaro Perez; Javier Gil; Jon Irazusta; José I López; M Luz Candenas; Francisco M Pinto; Gorka Larrinaga
Journal:  BMC Cancer       Date:  2010-05-11       Impact factor: 4.430

9.  Expression of claudin-7 in benign kidney and kidney tumors.

Authors:  Lin Li; Jorge L Yao; P Anthony di Sant'Agnese; Patricia A Bourne; Maria M Picken; Andrew N Young; Steven S Shen; Jiaoti Huang
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 10.  Biopsy of renal masses: when and why.

Authors:  V Anik Sahni; Stuart G Silverman
Journal:  Cancer Imaging       Date:  2009-07-06       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.